Mirna Therapeutics

Mirna’s lead product candidate, MRX34, is the first microRNA mimic to enter clinical development in oncology. MRX34 is being studied as a single agent in our ongoing open-label, multicenter Phase 1 clinical trial, which has included patients with primary liver cancer, other solid cancers, and hematological malignancies (lymphomas and leukemias). MRX34 was designed to deliver a mimic of the naturally occurring microRNA tumor suppressor miR-34, which is under expressed in a wide variety of cancers. MRX34 entered clinical testing in 2013.

Austin, US
Size (employees)
36 (est)+10%
Mirna Therapeutics is headquartered in Austin, US

Key People at Mirna Therapeutics

Paul Lammers

Paul Lammers

President & CEO
Jon Irvin

Jon Irvin

Sinil Kim

Sinil Kim

Vice President Oncology & Chief Medical Officer
David Brown

David Brown

Director, Discovery and in vivo Research
Andreas Bader

Andreas Bader

Director, Analytical and External Research

Mirna Therapeutics Office Locations

Mirna Therapeutics has an office in Austin
Austin, US (HQ)
2150 Woodward St

Mirna Therapeutics Data and Metrics

Mirna Therapeutics Financial Metrics


Net income (FY, 2016)

(26.3 m)

Market capitalization (20-Jul-2017)

34.4 m

Closing share price (20-Jul-2017)


Cash (31-Dec-2016)

16.4 m
Mirna Therapeutics's current market capitalization is $34.4 m.
USDFY, 2015FY, 2016

R&D expense

18.9 m13.9 m

General and administrative expense

6.1 m8.1 m

Operating expense total

25 m26.6 m

Interest income

44 k350 k

Net Income

(25 m)(26.3 m)
USDFY, 2015FY, 2016


89.7 m16.4 m


793 k882 k

Current Assets

90.5 m61.4 m


375 k354 k

Total Assets

90.9 m64.2 m

Accounts Payable

3.7 m361 k

Current Liabilities

5.9 m2.8 m

Total Liabilities

3.8 m

Additional Paid-in Capital

161.5 m163.1 m

Retained Earnings

(76.5 m)(102.8 m)

Total Equity

85 m60.4 m

Financial Leverage

1.1 x1.1 x
USDFY, 2015FY, 2016

Net Income

(25 m)(26.3 m)

Depreciation and Amortization

54 k159 k


793 k107 k

Accounts Payable

3.7 m(3.3 m)

Cash From Operating Activities

(21.1 m)(24.8 m)

Purchases of PP&E

(251 k)(1.7 m)

Cash From Investing Activities

(251 k)(48.5 m)

Cash From Financing Activities

67 k16 k
Y, 2016

Financial Leverage

1.1 x

Mirna Therapeutics Operating Metrics

FY, 2016

Patents Issued


Patents Pending


Mirna Therapeutics Market Value History

Mirna Therapeutics Company Life and Culture

You may also be interested in